The German biotech company Immatics Biotechnologies GmbH has become the latest European enterprise to list its shares on the US Nasdaq market in order to finance the development of immunotherapies for cancer. However Immatics chose an uncommon strategy for gaining market entry: it executed a reverse merger with a special purpose acquisition company.
Hong Kong-based Hutchison China MediTech Ltd (Chi-Med) has raised $100 million from a share placement with a global equity firm to support the development of its oncology business. The placement was with General Atlantic which has offices on four continents and a significant life science portfolio.
Netherlands-based BioGeneration Ventures has closed its fourth fund BGV IV at €105 million to continue its work building new companies in Europe around single assets or technology platforms. New investors included Industriens Pension of Denmark and KfW Capital of Germany, while Bristol-Myers Squibb Co, an investor in BioGeneration’s third fund, also participated in the new vehicle.
The France-based microbiome company Enterome SA has closed a €46.3 million Series E financing round to advance the development of a microbiome derived product for cancer. The financing was supported by Takeda Pharmaceutical Company Ltd, which also has a collaboration with the company, and the investors Seventure Partners and Nestlé Health Science.
Sanofi Pasteur, the vaccines arm of Sanofi SA, has reached an agreement with Translate Bio of the US to expand a two-year old collaboration in order to bring forward a candidate vaccine for COVID-19. The vaccine candidate uses messenger RNA (mRNA) technology and is expected to be ready for a first human trial in the fourth quarter of this year.
Epidarex Capital, the Edinburgh, UK-based venture capital firm, has closed a new fund to support early-stage UK life science companies. The fund raised £102.1 million at the close, of which £50 million represents a commitment from Enterprise Capital Funds, a government-supported scheme to help the growth of young businesses.
Oxford Biomedica Plc has raised a gross £40 million in a private share placement to support its ongoing gene therapy business which includes the manufacture of lentiviral vector for the Novartis product Kymriah. Kymriah was the first chimeric antigen receptor (CAR) T cell therapy to be approved for cancer. Most recently, Oxford Biomedica secured a contract with AstraZeneca Plc to manufacture an adenoviral vector based vaccine for COVID-19.
ISA Pharmaceuticals BV of the Netherlands has expanded a collaboration with Regeneron Inc to include a new trial for the companies’ combination treatment for human papillomavirus type 16 (HPV16)-induced cancers. The trial will recruit patients with oropharyngeal cancer, a type of head and neck cancer that affects tissues of the throat.
Within weeks of joining forces with the University of Oxford to develop a candidate vaccine for COVID-19, AstraZeneca Plc has secured manufacturing capacity to produce two billion doses of the prospective treatment as well as financial support of more than $1 billion from an agency of the US government. The company has harnessed resources quickly, even though vaccines are not one of its core therapy areas.
Genmab A/S has secured a broad antibody agreement with AbbVie Inc to develop up to seven new cancer products, putting it in a pole position to exploit new opportunities for therapies treating both solid tumours and haematological malignancies. Under the deal, the Denmark-based company will receive a $750 million upfront payment from AbbVie and is eligible for milestone payments potentially reaching $3.15 billion. Significantly, Genmab will have a 50% share of pre-tax profits from any future product sales as well as a say in decision-making.